Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors

NCT05397093 is registered in ClinicalTrials.gov with Instil Bio as lead sponsor.

NCT NCT05397093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05397093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Open-Label, Multicenter Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects With Advanced Solid Tumors
Lead sponsor
Instil Bio
Phase
Phase 1
Overall status
Terminated
Start date
August 24, 2022
Completion date
March 6, 2026
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, non-small cell lung cancer, renal cell carcinoma